SAB Biotherapeutics Inc (SABS) — Long-term Investment Intensity

Latest as of June 2026: 44.2%

SAB Biotherapeutics Inc (SABS) has a Long-term Investment Intensity of 44.2% as of June 2026. Long-term investments of $105.35 Million represent 44.2% of total assets of $238.21 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check asset resilience ratio of SAB Biotherapeutics Inc to evaluate the company's liquid asset resilience ratio.

LT Investment Intensity

44.2%
LT Investments / Total Assets

Long-term Investments

$105.35 Million
USD

Total Assets

$238.21 Million
USD

Country

USA
NASDAQ

SAB Biotherapeutics Inc Long-term Investment Intensity (2025–2025)

This chart shows how SAB Biotherapeutics Inc's Long-term Investment Intensity has evolved across 1 annual periods from 2025 to 2025. As of June 2026, the intensity stands at 44.2%, reflecting long-term investments of $105.35 Million against total assets of $238.21 Million USD. For the complete balance sheet picture, see SABS asset base.

Annual Long-term Investment Intensity for SAB Biotherapeutics Inc (2025–2025)

The table below presents the year-by-year Long-term Investment Intensity for SAB Biotherapeutics Inc from 2025 to 2025, covering 1 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read total liabilities of SAB Biotherapeutics Inc for a breakdown of total debt and financial obligations.

Year LT Investment Intensity LT Investments (USD) Total Assets Change (pp)
2025 27.1% $46.89 Million $172.81 Million
pp = percentage points